FUT3: A Potential Drug Target and Biomarker for Various Diseases

Target Name: FUT3

NCBI ID: G2525

FUT3

FUT3: A Potential Drug Target and Biomarker for Various Diseases

FUT3 (Leucine-rich repeat-containing protein 3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and muscles. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues.

Recent studies have identified FUT3 as a potential drug target (or biomarker) for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because FUT3 has been shown to play a role in the regulation of cellular processes that are implicated in the development and progression of these diseases.

One of the key mechanisms by which FUT3 is involved in the development and progression of cancer is its role in the regulation of cell proliferation. FUT3 has been shown to promote the growth and survival of cancer cells, and to inhibit the death of cancer cells that have become damaged or mutated. This suggests that FUT3 may be a useful target for the development of cancer therapies that target cell proliferation.

Another potential mechanism by which FUT3 may be involved in the development and progression of neurodegenerative diseases is its role in the regulation of cellular processes that are involved in the development and maintenance of the nervous system. FUT3 has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for the proper functioning of the nervous system.

FUT3 has also been shown to be involved in the regulation of cellular processes that are implicated in the development and progression of autoimmune disorders. In autoimmune disorders, the immune system attacks the body's own tissues and can cause a range of symptoms, including inflammation, pain, and damage to various body parts. FUT3 has been shown to play a role in the regulation of the immune system, and may be a useful target for the development of therapies for autoimmune disorders.

In addition to its potential as a drug target, FUT3 has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases. For example, FUT3 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and has been used as a biomarker for the diagnosis of this disease. Similarly, FUT3 has been shown to be expressed in the blood of individuals with Parkinson's disease, and has been used as a biomarker for the diagnosis of this disease.

Overall, FUT3 is a protein that has been shown to play a role in a variety of cellular processes that are important for the development and maintenance of tissues. As a result, FUT3 has potential as a drug target (or biomarker) for the treatment of various diseases. Further research is needed to fully understand the role of FUT3 in these processes, and to develop effective therapies that target FUT3.

Protein Name: Fucosyltransferase 3 (Lewis Blood Group)

Functions: Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to both the subterminal N-acetyl glucosamine (GlcNAc) of type 1 chain (beta-D-Gal-(1->3)-beta-D-GlcNAc) glycolipids and oligosaccharides via an alpha(1,4) linkage, and the subterminal glucose (Glc) or GlcNAc of type 2 chain (beta-D-Gal-(1->4)-beta-D-GlcNAc) oligosaccharides via an alpha(1,3) linkage, independently of the presence of terminal alpha-L-fucosyl-(1,2) moieties on the terminal galactose of these acceptors and participates in the blood groups Lewis determination and expression of Lewis a (Le(a)), lewis b (Le(b)), Lewis x/SSEA-1 (Le(x)) and lewis y (Le(y)) antigens (PubMed:12668675, PubMed:1977660, PubMed:11058871). Also catalyzes the transfer of L-fucose to subterminal GlcNAc of sialyl- and disialyl-lactotetraosylceramide to produce sialyl Lewis a (sLe(a)) and disialyl Lewis a via an alpha(1,4) linkage and therefore may regulate cell surface sialyl Lewis a expression and consequently regulates adhesive properties to E-selectin, cell proliferation and migration (PubMed:12668675, PubMed:11058871, PubMed:27453266). Catalyzes the transfer of an L-fucose to 3'-sialyl-N-acetyllactosamine by an alpha(1,3) linkage, which allows the formation of sialyl-Lewis x structure and therefore may regulate the sialyl-Lewis x surface antigen expression and consequently adhesive properties to E-selectin (PubMed:11058871, PubMed:29593094). Prefers type 1 chain over type 2 acceptors (PubMed:7721776). Type 1 tetrasaccharide is a better acceptor than type 1 disaccharide suggesting that a beta anomeric configuration of GlcNAc in the substrate is preferred (PubMed:7721776). Lewis-positive (Le(+)) individuals have an active enzyme while Lewis-negative (Le(-)) individuals have an inactive enzyme (PubMed:1977660)

The "FUT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FUT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets